Early effects of transplatin on oncogene activation in vivo

Árpád Németh, E. Nádasi, A. Beró, L. Olasz, Á Ember, A. Kvarda, L. Bujdosó, I. Arany, A. Csejtei, Zs Faluhelyi, I. Ember

Research output: Contribution to journalArticle

1 Citation (Scopus)


The aim of the study was to investigate the early effect of Transplatin (the stereo-homer of Cisplatin) on oncogenes in inbred CBA/Ca mice. Cisplatin is commonly used for the treatment of squamous cell carcinomas of the head and neck. Cisplatin has a strong oncogene activation effect compared to the structural analogue Transplatin. Body weight equivalent amounts of a human dose of Transplatin were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the expressions of c-myc, Ha-ras and p53 genes were examined. Investigation of early changes showed no significant overexpression compared to Cisplatin, which had a significant effect on oncogene expression in the "short-term" in vivo test system.

Original languageEnglish
Pages (from-to)3997-4001
Number of pages5
JournalAnticancer research
Issue number6
Publication statusPublished - Nov 1 2004


  • Head and neck cancer
  • Oncogene expression
  • Platinum isomers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Early effects of transplatin on oncogene activation in vivo'. Together they form a unique fingerprint.

  • Cite this

    Németh, Á., Nádasi, E., Beró, A., Olasz, L., Ember, Á., Kvarda, A., Bujdosó, L., Arany, I., Csejtei, A., Faluhelyi, Z., & Ember, I. (2004). Early effects of transplatin on oncogene activation in vivo. Anticancer research, 24(6), 3997-4001.